We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

Download Mobile App




New Liquid Biopsy Assay Reveals Host-Pathogen Interactions

By LabMedica International staff writers
Posted on 09 Sep 2019
Print article
Image: A micrograph of a urine cytology specimen showing a polyomavirus infected cell (Photo courtesy of Wikimedia Commons).
Image: A micrograph of a urine cytology specimen showing a polyomavirus infected cell (Photo courtesy of Wikimedia Commons).
A sensitive new assay employs high-throughput DNA sequencing to identify a large range of viral and bacterial pathogens in clinical samples, distinguish them from host DNA, and determine the degree of host tissue injury due to interaction with the pathogens.

While high-throughput DNA sequencing offers an unbiased approach to identify pathogens in clinical samples, this method does not take into account information about the host, which is often critical to distinguish infection from infectious disease, and to assess the severity of disease.

To provide more information about the host-pathogen relationship, investigators at Cornell University (Ithaca, NY, USA) developed a liquid biopsy technique to map cell-free DNA (cfDNA) from clinical samples such as blood and urine. This assay simultaneously quantified the abundance of a large range of viral and bacterial pathogens as well as the degree of host tissue injury from host–microorganism interaction. This was accomplished with a genome-wide measurement of cell-free DNA methylation marks via bisulfite sequencing, a process in which the cell-free DNA was treated with salt to reveal methylation marks.

Bisulfite sequencing to determine the pattern of methylation was performed following treatment of DNA with bisulfite. Treatment of DNA with bisulfite converted cytosine residues to uracil, but left 5-methylcytosine residues unaffected. Therefore, DNA that had been treated with bisulfite retained only methylated cytosines. Bisulfite treatment introduced specific changes in the DNA sequence that depended on the methylation status of individual cytosine residues, yielding single-nucleotide resolution information about the methylation status of a segment of DNA.

The investigators applied the new assay technique to analyze 51 urinary cfDNA isolates collected from a cohort of kidney transplant recipients with and without bacterial and viral infection of the urinary tract. They found that the cell and tissue types of origin of urinary cfDNA could be derived from its genome-wide profile of methylation marks, and strongly depended on infection status. Furthermore, they found evidence of kidney and bladder tissue damage due to viral and bacterial infection, respectively, and of the recruitment of neutrophils to the urinary tract during infection. Through direct comparison to conventional DNA sequencing as well as clinical tests of infection, they found that this assay accurately captured the bacterial and viral composition of the sample.

In particular, the investigators demonstrated that kidney-specific urine cell-free DNA was higher in individuals with BK polyomavirus (BKV nephropathy) as compared to those with BKV replication alone and those with no BKV replication, suggesting a role for this assay to monitor kidney damage in the face of active viral replication and infection.

Senior author Dr. Iwijn De Vlaminck, professor of biomedical engineering at Cornell University, said, "So we developed an assay that would simultaneously inform us about the presence or absence of a wide range of pathogens, but at the same time would also tell us about the injury of different host tissues. The combined information enables us to more definitively say whether a person is dealing with disease or not. But there was still a big gap to assess whether that organism is actually causing disease. That is really a critical question, because some organisms are just commensals, they live side by side with the host. Our guts are filled with microbes, but those microbes may not be the reason you are suffering from disease. In a way, you are infected. You are colonized, but that is just part of normal biology."

The new assay method was described in the August 26, 2019, online edition of the journal Proceedings of the [U.S.] National Academy of Sciences.

Related Links:
Cornell University

Gold Supplier
Blood Glucose Laboratory Analyzer
Nova Primary
New
Silver Supplier
COVID-19 Ag Self Test
OnSite COVID-19 Ag Self Test
New
Respiratory Multiplex RT-PCR Kit
Respiratory Multiplex RT-PCR Kit
New
Assayed Hemoglobin Control
https://www.eurotrol.com/en/spotlights/hemotrol-wb/

Print article

Channels

Molecular Diagnostics

view channel
Image: Absence of nuclear immunohistochemical staining of MSH2 protein (A) and presence of MLH1 protein (B) in urothelial cell carcinoma of the urinary bladder of a patient carrying a germline MSH2 mutation. Observe the nuclear staining in stromal cells as an internal control (Photo courtesy of Radboud University Nijmegen Medical Centre)

Simple Urine Test Detects Urothelial Cancers in Lynch Syndrome Patients

Lynch Syndrome (LS) is an inherited genetic disorder that carries a high risk of cancer. LS is caused by mutations affecting MLH1, MSH2, MSH6 or PMS2 genes. More than one in 300 people have LS but most... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test for screening, diagnosis and management of sickle cell disease and related hemoglobinopathies at the point of care (Photo courtesy of Hemex Health)

Point-of-Care Device Accurately Rapidly Diagnoses Sickle Cell Disease

Hemoglobinopathies are the most common autosomal hereditary disorders. Approximately 7% of the global population carries hemoglobin gene mutation including structural hemoglobin variants like sickle hemoglobin... Read more

Immunology

view channel
Image: The IMMULITE 2000 XPi Immunoassay System provides multiple tests on a single, easy-to-use analyzer, including the thyroid-stimulating immunoglobulin assay (Photo courtesy of Siemens Healthcare)

Immunoassays Evaluated for Thyroid-Stimulating Receptor Antibody in Graves’ Disease

Graves' disease (GD), also known as toxic diffuse goiter, is an autoimmune disease that affects the thyroid. It frequently results in and is the most common cause of hyperthyroidism and it also often results... Read more

Microbiology

view channel
Image: The sciREADER CL2 enables high quality digital colorimetric imaging of various support formats (Photo courtesy of SCIENION)

Multiplex Immunoassay Developed for Confirmation and Typing of HTLV Infections

Human T-Cell Lymphotropic Viruses (HTLV) type 1 and type 2 account for an estimated five to 10 million infections worldwide and are transmitted through breast feeding, sexual contacts and contaminated... Read more

Pathology

view channel
Illustration

AI Accurately Detects and Diagnoses Colorectal Cancer from Tissue Scans As Well or Better Than Pathologists

Artificial intelligence (A) can accurately detect and diagnose colorectal cancer from tissue scans as well or better than pathologists, according to a new study. The study, which was conducted by researchers... Read more

Technology

view channel
Image: PKeye Workflow Monitor System (Photo courtesy of PerkinElmer, Inc.)

PerkinElmer’s New Cloud-Based Platform Enables Laboratory Personnel to Remotely Manage Its Instruments in Real-Time

PerkinElmer, Inc. (Waltham, MA; USA) has launched its PKeye Workflow Monitor, a cloud-based platform enabling laboratory personnel to remotely manage and monitor their PerkinElmer instruments and workflows... Read more

Industry

view channel
Illustration

Global Point of Care Diagnostics Market to Top USD 35 Billion by 2027 Due to Rising Diabetic Cases

The global point of care diagnostics market is projected to grow at a CAGR of close to 6% from more than USD 23 billion in 2020 to over USD 35 billion by 2027, driven by an increase in the number of diabetic... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.